B. Ely

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)

C. Gotay, H. Lenz, A. Shields, 2013, British Journal of Cancer.

Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917

D. Alberts, I. Thompson, C. Tangen, 2011, Cancer Prevention Research.

Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia : SWOG S 9917

D. Alberts, I. Thompson, C. Tangen, 2011 .

Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology

E. Messing, I. Thompson, C. Tangen, 2011 .

Intermittent versus continuous androgen deprivation in prostate cancer.

Donna L Berry, Ian M Thompson, Stephen Prescott, 2013, The New England journal of medicine.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

I. Thompson, C. Tangen, L. Fink, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial

Y. Tai, I. Thompson, C. Tangen, 2015, International journal of cancer.

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

E. Messing, I. Thompson, C. Tangen, 2010, BJU international.

TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL ONCOLOGISTS FROM: SWOG Operations Office RE: IND Safety Reports for IMC-A12 MEMORANDUM

H. Gundacker, C. Tangen, C. Rankin, 2011 .

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

I. Thompson, C. Tangen, A. Goldkorn, 2014, Journal of the National Cancer Institute.

Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC).

Y. Tai, I. Thompson, C. Tangen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.